摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-Piperazin-1-ylphenyl)-2-propan-2-yl-1,2,4-triazol-3-one | 210563-19-2

中文名称
——
中文别名
——
英文名称
4-(4-Piperazin-1-ylphenyl)-2-propan-2-yl-1,2,4-triazol-3-one
英文别名
——
4-(4-Piperazin-1-ylphenyl)-2-propan-2-yl-1,2,4-triazol-3-one化学式
CAS
210563-19-2
化学式
C15H21N5O
mdl
——
分子量
287.365
InChiKey
HQWZCFWJLGTDIE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    51.2
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    4-(4-Piperazin-1-ylphenyl)-2-propan-2-yl-1,2,4-triazol-3-one三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.5h, 生成
    参考文献:
    名称:
    [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES
    [FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
    摘要:
    本发明涉及新颖的芳基哌啶或哌嗪化合物,其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法,包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途(公式(I))。该发明还涉及制备这种化合物的方法,包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
    公开号:
    WO2005085226A1
  • 作为产物:
    描述:
    Ethyl 4-[4-(5-oxo-1-propan-2-yl-1,2,4-triazol-4-yl)phenyl]piperazine-1-carboxylate 在 氢溴酸sodium hydrogensulfite 作用下, 以 为溶剂, 反应 5.0h, 生成 4-(4-Piperazin-1-ylphenyl)-2-propan-2-yl-1,2,4-triazol-3-one
    参考文献:
    名称:
    [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES
    [FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
    摘要:
    本发明涉及新颖的芳基哌啶或哌嗪化合物,其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法,包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途(公式(I))。该发明还涉及制备这种化合物的方法,包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
    公开号:
    WO2005085226A1
点击查看最新优质反应信息

文献信息

  • NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS
    申请人:Naeja Pharmaceutical Inc.
    公开号:EP0889881B1
    公开(公告)日:2003-04-23
  • NOVEL CRYSTALLINE HETEROAROMATIC FLUOROGLYCOSIDE HYDRATES, PHARMACEUTICALS COMPRISING THESE COMPOUNDS AND THEIR USE
    申请人:SANOFI
    公开号:EP2470552B1
    公开(公告)日:2013-11-13
  • Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles
    申请人:Meerpoel Lieven
    公开号:US20070191383A1
    公开(公告)日:2007-08-16
    The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.
  • MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES
    申请人:Meerpoel Lieven
    公开号:US20100004263A1
    公开(公告)日:2010-01-07
    The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.
  • US7504400B2
    申请人:——
    公开号:US7504400B2
    公开(公告)日:2009-03-17
查看更多